AYTU Bioscience, Inc.
AYTU Bioscience, Inc. is listed today as Aytu Bioscience: market value, financials and filings are on its company page.
Funding rounds
0 counted as startup funding, 3 other private sales on record. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Oct 2019 | $10 M | Private placement after listing | $10 to $50 million | equity, options | SEC | |
| Aug 2017 | $12 M | Private placement after listing | $10 to $50 million | equity, options | SEC | |
| May 2017 | $2 M | Private placement after listing | Under $2 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
As the listed company Aytu Bioscience, its revenue in fiscal 2026 came from these product and service lines: ADHD Portfolio $45.82 million (80%), E X X U A Portfolio $6.57 million (11%), The Pediatric Portfolio $5.14 million (9%), Product and Service, Other $40,000 (0%).
Annual report (SEC XBRL) · Jun 2026
AYTU Bioscience, Inc. chose not to state its revenue in its newest notice of a funding round (Oct 2019).
SEC Form D · Oct 2019
The industry group it chose in its notices: Pharmaceuticals.
SEC Form D · Oct 2019
Products and services#
No products or services of AYTU Bioscience, Inc. are on record.
Investors#
1 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Cerecor Inc. | Company | not stated | not stated | Held preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete.
Largest shareholders today
Institutions holding Aytu Bioscience shares, as of Sep 30, 2026.
- Nantahala Capital Management, LLC$2 M10.00%
- Stonepine Capital Management, LLC$2 M8.88%
- AWM Investment Company, Inc.$1 M5.70%
- Vanguard Capital Management LLC$1 M2.40%
- Crown Advisors Management, Inc.$0 M1.84%
- Geode Capital Management, LLC$0 M1.14%
- Renaissance Technologies LLC$0 M1.12%
- Diadema Partners LP$0 M0.62%
- Two Sigma Investments, LP$0 M0.60%
- Dimensional Fund Advisors LP$0 M0.46%
- Vanguard Fiduciary Trust Co$0 M0.44%
- Northern Trust Corp$0 M0.26%
- BlackRock, Inc.$0 M0.21%
- Persistent Asset Partners Ltd$0 M0.16%
- Citadel Advisors LLC$0 M0.12%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| David Green | Executive officer | Oct 2019 |
| Jarrett Disbrow | Executive officer | Oct 2019 |
| Josh Disbrow | Executive officer | Oct 2019 |
| Gregory A. Gould | Executive officer | Aug 2017 |
| Jarrett T. Disbrow | Executive officer | Aug 2017 |
| Joshua R. Disbrow | Executive officer | Aug 2017 |
| Carl Dockery | Director | Oct 2019 |
| Gary Cantrell | Director | Oct 2019 |
| John Donofrio Jr. | Director | Oct 2019 |
| Josh Disbrow | Director | Oct 2019 |
| Ketan Mehta | Director | Oct 2019 |
| Michael Macaluso | Director | Oct 2019 |
| Steven Boyd | Director | Oct 2019 |
| Carl C. Dockery | Director | Aug 2017 |
| Gary V. Cantrell | Director | Aug 2017 |
| John A. Donofrio, Jr. | Director | Aug 2017 |
| Joshua R. Disbrow | Director | Aug 2017 |
| Michael A. Macaluso | Director | Aug 2017 |
Went public since 2013. Its SEC number is that of a company listed on a stock exchange.